(Q37292462)

19 August 2017

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1

Douglas T Ross

1 reference

19 August 2017

Chung-Yeul Kim

2

1 reference

19 August 2017

Gong Tang

3

1 reference

19 August 2017

Olga L Bohn

4

1 reference

19 August 2017

Rodney A Beck

5

1 reference

19 August 2017

Brian Z Ring

6

1 reference

19 August 2017

Robert S Seitz

7

1 reference

19 August 2017

Soonmyung Paik

8

1 reference

19 August 2017

Joseph P Costantino

9

1 reference

19 August 2017

Norman Wolmark

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

Clinical Cancer Research

1 reference

19 August 2017

14

1 reference

19 August 2017

20

1 reference

19 August 2017

6602-6609

1 reference

Concordance among gene-expression-based predictors for breast cancer

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Prognostic factors in breast cancer: current and new predictors of metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Traditional and newer pathologic factors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

A new approach to the validation of tissue microarrays.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Recommendations for Improved Standardization of Immunohistochemistry

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2722068

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18927301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-08-0647

1 reference

19 August 2017

1 reference

19 August 2017

1 reference